SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

RPG Life Sciences - Quaterly Results

29 Apr 2022 Evaluate
The company witnessed a 11.90% growth in the revenue at Rs. 1038.00 millions for the quarter ended March 2022 as compared to Rs. 927.60 millions during the year-ago period.The Company has registered profit of Rs. 75.20  millions for the quarter ended March 2022, a growth of 8.67%  over Rs. 69.20 millions millions achieved in the corresponding quarter of last year.Operating Profit saw a handsome growth to 147.70 millions from 129.60 millions in the quarter ended March 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 1038.00 927.60 11.90 4401.60 3891.40 13.11 4401.60 3891.40 13.11
Other Income 12.60 3.00 320.00 29.90 9.10 228.57 29.90 9.10 228.57
PBIDT 147.70 129.60 13.97 893.50 708.40 26.13 893.50 708.40 26.13
Interest 0.60 0.90 -33.33 5.20 7.90 -34.18 5.20 7.90 -34.18
PBDT 147.10 128.70 14.30 888.30 700.50 26.81 888.30 700.50 26.81
Depreciation 37.80 39.20 -3.57 156.60 164.70 -4.92 156.60 164.70 -4.92
PBT 109.30 89.50 22.12 731.70 535.80 36.56 731.70 535.80 36.56
TAX 34.10 20.30 67.98 216.90 135.80 59.72 216.90 135.80 59.72
Deferred Tax -6.90 -9.20 -25.00 -10.70 -35.70 -70.03 -10.70 -35.70 -70.03
PAT 75.20 69.20 8.67 514.80 400.00 28.70 514.80 400.00 28.70
Equity 132.30 132.30 0.00 132.30 132.30 0.00 132.30 132.30 0.00
PBIDTM(%) 14.23 13.97 1.85 20.30 18.20 11.51 20.30 18.20 11.51

RPG Life Sciences Share Price

2039.05 28.45 (1.42%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×